+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sarepta Therapeutics - logo

Sarepta Therapeutics is a biopharmaceutical company that focuses on the development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD). It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

From
From
From
From
From
West Nile Virus Infections Global Clinical Trials Review, H2, 2018 - Product Thumbnail Image

West Nile Virus Infections Global Clinical Trials Review, H2, 2018

  • Clinical Trials
  • September 2018
  • 37 pages
From
Dystrophin - Pipeline Review, H2 2020 - Product Thumbnail Image

Dystrophin - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 128 pages
From
Dystrophin (DMD) - Pipeline Review, H2 2019 - Product Thumbnail Image

Dystrophin (DMD) - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 117 pages
From
From
From
From
Muscular Dystrophy Disease - Global Clinical Trials Review, H2, 2020 - Product Thumbnail Image

Muscular Dystrophy Disease - Global Clinical Trials Review, H2, 2020

  • Clinical Trials
  • November 2020
  • 113 pages
From
From
From
From
From
Loading Indicator
adroll